Navigation Links
Life Sciences Discovery Fund Awards $2.2 Million to Support New Solid-Tumor Research Program
Date:4/17/2008

SEATTLE, April 17 /PRNewswire/ -- The state's Life Sciences Discovery fund has awarded $2.2 million to establish a formal phase 1 clinical-trials program to test new therapies for solid tumors at Fred Hutchinson Cancer Research Center. Announced this evening, the grant is among the first funded by Washington's $350 million tobacco-lawsuit-settlement bonus.

Developing novel therapies targeted to treat solid tumors, in collaboration with local biotechnology and pharmaceutical firms, is the goal of the Hutchinson Center/University of Washington Cancer Consortium. Phase 1 trials are by definition the first testing of cancer therapies in humans. The purpose is to determine whether and how a drug works.

Traditionally, phase 1 studies have been primarily concerned with drug safety. However, with the increased knowledge of the molecular pathways involved in cancer development, an ever-increasing proportion of drugs initially tested in humans prove to be effective, even in the first patients treated.

"Phase 1 trials are critically important, require a high level of unique competencies and, if done correctly, can substantially speed the development of new therapies," said Martin (Mac) Cheever, M.D., director of solid-tumor research at the Hutchinson Center. "This is an outcome that can benefit the state's patients, industry and health care enterprises."

Initially, the program will use the funding to develop a highly efficient infrastructure for implementing early phase -- primarily industry sponsored -- cancer clinical trials, and to provide exploratory funds that will allow Consortium researchers to apply their expertise in cancer imaging and biomarkers to cancer drug development.

The program will be led by John Thompson, M.D., as director of the Consortium phase 1 program. Thompson will be responsible for scientific direction and facilitating new industry and other trial sponsorships.

"Standard therapy for cancer is clearly i
'/>"/>

SOURCE Fred Hutchinson Cancer Research Center
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
2. Edwards Lifesciences to Present at the Bear Stearns 20th Annual Healthcare Conference
3. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
4. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
5. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
6. Novavax CEO to Present at the 2007 UBS Global Life Sciences Conference
7. Cardiac Science to Present at the UBS Global Life Sciences Conference
8. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
9. DRAXIS to Present at the 2007 UBS Global Life Sciences Conference
10. ViroPharma to Present at the UBS Global Life Sciences Conference
11. Clarient to Present at the UBS 2007 Global Life Sciences Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... This November, Home Care Delivered joins...ovement to raise awareness for a disease that affe... Richmond, VA (Vocus) November 24, 2009 -- In co...ADA), Home Care Delivered recognizes National Di...he month of November. Nearly 24 million Americans ...
(Date:11/24/2009)...,Nov.24/PRNewswire-FirstCall/--USFarms,Inc.,(PinkS...dWellnessproductsispleasedtoannounceithasreceivedf...ssociation(AVA)foritsAloe365(TM)Juiceproduct. ,...sedtoannouncethatwehavecompletedthecertificationpr...oz.Aloe365(TM)Juice.TheprimarygoaloftheAVAistoprov...
(Date:11/24/2009)...LLE,N.C.,Nov.24/PRNewswire/--TheAmericanSocietyofE...asurveyabouttheimpactofthe2010CMSPhysicianFeeSched...istsandcardiovascularultrasoundtechnicianssurveyed...pacceptingMedicarepatients,reducestafforshutdownth...cesstoechocardiography(heartultrasound)andothervit...
(Date:11/24/2009)...ed with online predators, but few fear cyberbullyi...ealthDay News) -- More than four in five parents s...upervision, but at the same time almost two-thirds...has found. , The findings, released online Nov....Poll on Children,s Health, show that parents have ...
(Date:11/24/2009)...,Israel,November24/PRNewswire-FirstCall/--ICL(TASE...lscompany,todayreported,resultsforthethirdquartera...lResultsfortheThirdQuarter , Revenues:Revenue...scomparedsequentiallywith$1,083millionforthesecond...e$2,178million,reflecting,theexceptionaldemandandp...
Breaking Medicine News(10 mins):Health News:Home Care Delivered, Inc. Recognizes November as National Diabetes Awareness Month 2Health News:Home Care Delivered, Inc. Recognizes November as National Diabetes Awareness Month 3Health News:US Farms, Inc. Receives American Vegetarian Association Certification Approval for Aloe365(TM) Juice Product 2Health News:Lives Compromised and Patient Access Limited with New Cuts to Medicare 2Health News:Parents Worry About Their Kids' Safety on the Internet 2Health News:ICL Reports Continued Sequential Improvement for Third Quarter of 2009 2Health News:ICL Reports Continued Sequential Improvement for Third Quarter of 2009 3Health News:ICL Reports Continued Sequential Improvement for Third Quarter of 2009 4Health News:ICL Reports Continued Sequential Improvement for Third Quarter of 2009 5Health News:ICL Reports Continued Sequential Improvement for Third Quarter of 2009 6Health News:ICL Reports Continued Sequential Improvement for Third Quarter of 2009 7
...of the most prestigious awards in nursing, The Mag...al (AMH) for its Daily CARE Plan at the National M...This was the sixth year the award was presented. ...bington Memorial Hospital (AMH) for its Daily CAR...
... a commitment to helping seniors and their familie...HealthCare Partners Medical Group and Affiliated P...care Benefits for 2009" comparison presentati...t to helping seniors and their families understand...
...thCare Partners is being recognized as one of the ...Integrated Healthcare Association for the fifth st...ur California Physicians groups in the greater Los...tners was named by the Integrated Healthcare Assoc...
...er in mobile computing and medication carts unveil...odate most laptop models. , ...olumbus, OH based medical product developer, Artro...uter carts allow hospitals to fully mobilize their...
...er 11 , - Guests Will Bounce Back to Health Using...ing healthy in these stressful times is a challeng...h Retreats early in 2009 may provide,participants ... bouncing gently on a mini-trampoline several time...
... The 2008 Frost &,Sullivan European Health Ingredi... recognition of its pioneering efforts in developi... health problems., "Rather than cure, current med...ORTIGEL(R) represents the first,ingredient in both...
Other Medicine News:Health News:Abington Memorial One of Just Six Hospitals in the U.S. to Win Magnet Prize 2Health News:Abington Memorial One of Just Six Hospitals in the U.S. to Win Magnet Prize 3Health News:Healthcare Partners Medical Group to Host Free Medicare Benefits Presentations 2Health News:Healthcare Partners Medical Group to Host Free Medicare Benefits Presentations 3Health News:Healthcare Partners Medical Group to Host Free Medicare Benefits Presentations 4Health News:HealthCare Partners Rated A 'Top Performing California Physician Group' By IHA For the Fifth Straight Year 2Health News:HealthCare Partners Rated A 'Top Performing California Physician Group' By IHA For the Fifth Straight Year 3Health News:Mobile Computing Carts Leader to Release New Clinical Computer Cart 2Health News:New Health Retreat Gives a Fresh Attitude Towards Disease Prevention 2Health News:Frost & Sullivan Honours GELITA for Developing European Health Ingredient of the Year 2Health News:Frost & Sullivan Honours GELITA for Developing European Health Ingredient of the Year 3
(Date:11/23/2009)...wswire-FirstCall/--TransceptPharmaceuticals,Inc.(N...withtheU.S.FoodandDrugAdministration(FDA)onJanuary...theNewDrugApplication(NDA)for Intermezzo ® (...unced,theCompleteResponseLetter,receivedbyTranscep...vetheNDAinitspresentform.TheNDAseeksapprovaltomark...
(Date:11/23/2009)...swire-FirstCall/--Amgen(Nasdaq: AMGN )washonoredwi...andforBestNewDrugforNplate®(romiplostim),ataN...eawardwaspresentedtoAmgenbyScripinrecognitionofthe...,spipeline,aswellasitsmixofcandidatesacrossdevelop...otableforitsfocusonunmetclinicalneed. ,, "Weare...
(Date:11/23/2009)...rtlinker.comannouncesthatanewmarketresearchreporti...sInvestmentOpportunities,AnalysisandForecaststo201...dia-Dental-Devices-Investment-Opportunities-Analys...e&utm_medium=pr&utm_campaign=prnewswire ...stmentOpportunities,AnalysisandForecaststo2015 ,...
Breaking Medicine Technology:Transcept Pharmaceuticals Scheduled to Meet With FDA to Discuss Intermezzo(R) Complete Response Letter 2Amgen Recognized for Best Pipeline and Best New Drug at Scrip Awards 2Amgen Recognized for Best Pipeline and Best New Drug at Scrip Awards 3Amgen Recognized for Best Pipeline and Best New Drug at Scrip Awards 4Amgen Recognized for Best Pipeline and Best New Drug at Scrip Awards 5Amgen Recognized for Best Pipeline and Best New Drug at Scrip Awards 6Reportlinker Adds India Dental Devices Investment Opportunities, Analysis and Forecasts to 2015 2Reportlinker Adds India Dental Devices Investment Opportunities, Analysis and Forecasts to 2015 3Reportlinker Adds India Dental Devices Investment Opportunities, Analysis and Forecasts to 2015 4Reportlinker Adds India Dental Devices Investment Opportunities, Analysis and Forecasts to 2015 5Reportlinker Adds India Dental Devices Investment Opportunities, Analysis and Forecasts to 2015 6Reportlinker Adds India Dental Devices Investment Opportunities, Analysis and Forecasts to 2015 7Reportlinker Adds India Dental Devices Investment Opportunities, Analysis and Forecasts to 2015 8Reportlinker Adds India Dental Devices Investment Opportunities, Analysis and Forecasts to 2015 9Reportlinker Adds India Dental Devices Investment Opportunities, Analysis and Forecasts to 2015 10Reportlinker Adds India Dental Devices Investment Opportunities, Analysis and Forecasts to 2015 11Reportlinker Adds India Dental Devices Investment Opportunities, Analysis and Forecasts to 2015 12Reportlinker Adds India Dental Devices Investment Opportunities, Analysis and Forecasts to 2015 13Common chemotherapy drug triggers fatal allergic reactions 8748 1Common chemotherapy drug triggers fatal allergic reactions 8748 2Common chemotherapy drug triggers fatal allergic reactions 8748 3Nonin Medical Introduces Next Generation Regional Oximeter at Euroanaesthesia 2009 48203 1Nonin Medical Introduces Next Generation Regional Oximeter at Euroanaesthesia 2009 48203 2Sleeplessness a Weighty Matter 48202 1Sleeplessness a Weighty Matter 48202 2
...ermillion, Inc.,(OTC Bulletin Board: VRML) announc... to extend the Strategic Alliance Agreement betwee...n will enable the companies to continue,work on th...OVA1(TM) and,VASCLIR(TM)., The OVA1 test is inten... at high risk of being malignant. Data from a 27-s...
...DHD stimulant medication with published data,demon...a pediatric clinical,study, CHICAGO, Oct. 29 Shi...alty biopharmaceutical company, today announced,re...ool-aged children aged,6 to 12 years with Attentio...tudy, researchers found that VYVANSE controlled AD...
Other Medicine Technology:Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc. 2Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc. 3Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc. 4Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD 2Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD 3Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD 4Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD 5Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD 6Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD 7
Seditainer Blood Collection Tube For Erythrocyte Sedimentation Rate Determination
...22® Test Kit is a quantitative microplate enzy...tients who are at risk for rapid recurrence or occ...ded urine sample and is twice as sensitive as urin...rove patient outcome by identifying those patients...
Hemoccult SENSA Fecal Occult Blood Test
Luna Fertility Indicator
Medicine Products: